Microsoft Corporation (MSFT.US) plans to cut up to 2.5% of its workforce in the latest round of layoffs, with the plan potentially being announced as early as next week, Business Insider, citing sources, reported.

The layoffs are expected to affect thousands of positions, including sales and consulting roles, as well as positions in the Xbox gaming division.

As of the end of June last year, Microsoft had approximately 228,000 full-time employees.
~

AASTOCKS Financial News
Website: www.aastocks.com

BYD COMPANY (01211.HK) delivered 557,100 EVs in 2Q26, Bloomberg reported. Although the figure subsided YoY, it may still be enough to topple Tesla, Inc. (TSLA.US), as Tesla is expected to report quarterly sales of about 396,500 vehicles next week.

BYD COMPANY first surpassed Tesla in sales in 4Q24 and maintained a noticeable lead last year. However, Tesla regained the lead in 1Q26, with sales exceeding BYD COMPANY by about 48,000 vehicles, as feeble demand in the China market weighed on BYD COMPANY's domestic sales.

As China's automobile market remains mired in an intense price war, BYD COMPANY is focusing on technology upgrades while aggressively expanding into overseas markets. About 43% of its second-quarter sales stemmed from overseas markets.
~

AASTOCKS Financial News
Website: www.aastocks.com

全球唯一入選世界指數及亞太指數之綜合旅遊休閒企業
「人才、社區及地球」三大ESG策略成效備受國際肯定

澳門2026年7月1日 /美通社/ -- 金沙中國有限公司憑藉在環境、社會及管治（Environmental, Social and Governance, ESG）方面的卓越表現，在最新公佈的道瓊斯可持續發展指數（Dow Jones Best-in-Class Indices）評選中，連續第五年入選道瓊斯可持續發展世界指數，以及連續第六年入選道瓊斯可持續發展亞太指數，成為全球唯一同時入選世界指數及亞太指數之綜合旅遊休閒企業，充分肯定公司在「人才、社區及地球」三大可持續發展核心方向的卓越表現及成效。

在今年的評選中，全球共有16家綜合旅遊休閒企業獲邀參與，最終僅有金沙中國及母公司拉斯維加斯金沙集團雙雙入選世界指數；金沙中國亦是僅有兩家躋身亞太指數的綜合旅遊休閒企業之一。此外，拉斯維加斯金沙集團此次亦連續第七年獲列入世界指數及北美指數，印證集團一體化的ESG管理成效備受國際肯定。

金沙中國有限公司行政總裁兼執行董事鄭君諾表示：「金沙中國今年再度獲納入道瓊斯可持續發展世界指數及亞太指數，成為全球唯一同時入選此兩大指標的綜合旅遊休閒企業，我們對此深感榮幸。這份殊榮充分肯定公司在環境、社會及企業管治範疇的傑出表現，獲國際機構高度肯定令人鼓舞。金沙中國一直視可持續發展為公司重要基石，堅持履行企業社會責任。二十多年來，我們將ESG理念貫徹於日常營運，推動本澳人才培育發展、社區共融、支持中小企等多項工作，致力為澳門開創更廣泛、更長遠的社會效益。未來，我們將持續堅持可持續發展理念與實踐，並與澳門特區政府及社會各界緊密合作，為澳門共創更綠色、美好、多元的未來。」

一直以來，金沙中國堅定履行「人才」、「社區」及「地球」三大企業責任支柱，並推行一系列相關的可持續發展舉措。在人才方面，公司透過金沙中國學院於2025年向本地僱員提供累計合共180萬培訓小時；自澳門金沙於2004年開業至2025年底，公司為團隊成員提供的累計培訓總時數已超過2,260萬小時。

在社區層面，金沙中國於2009年成立「金沙中國關懷大使計劃」，成為全澳首家設立義工隊的綜合旅遊休閒企業；截至2025年，計劃已累計貢獻高達362,000個社區服務小時。與此同時，金沙中國亦積極配合澳門特區政府推動社區經濟及片區活化的施政方針，持續投放企業資源，為歷史片區的可持續發展注入動能。公司早前以「融舊立新‧承先啟後」理念，再度推出「草堆街片區活化項目」，鼓勵及支持澳門中小企在草堆街開創及優化其業務，攜手激活街區經濟活力。

在環境管理方面，金沙中國持續推進各項減碳與環保措施。與2018基準年相比，公司已成功將範疇一及範疇二的溫室氣體排放量大幅削減61%，一系列高效的綠色舉措亦令金沙中國早前再度榮獲ISO 14001環境管理體系認證。此外，公司亦透過多項具體行動持續優化資源運用及提升營運效益，包括全面落實娛樂場撲克牌100%回收再造、將所有免費樽裝水全面更換為環保材質，以及持續擴大非籠養鷄蛋等綠色採購比例。

道瓊斯可持續發展指數於1999年推出，是全球首個亦是最具公信力的企業可持續發展基準系列。該指數由標普全球（S&P Global）每年對全球逾12,000家企業進行深度評審，嚴格全面地評估各行業在ESG範疇的表現。其評選結果不僅是全球可持續發展投資者的核心指標，亦是國際公認評估企業長期商業成功與管治水平的權威榮譽。

關於金沙中國有限公司

金沙中國有限公司（香港聯交所：1928，「金沙中國」或「公司」）是一所於開曼群島註冊成立的有限公司及在香港聯合交易所有限公司上市的公司。金沙中國是澳門最大的綜合度假村經營商，於路氹金光大道上設有澳門威尼斯人^®、澳門百利宮、澳門巴黎人^®，以及澳門倫敦人^® 等物業項目，同時擁有及經營位於澳門半島的澳門金沙。公司旗下的各綜合度假村集合多樣化的娛樂消閒、商務設施及客運業務，包括大型會議及展覽場地、各式餐廳食肆、購物中心、於威尼斯人綜藝館、倫敦人綜藝館、威尼斯人劇場、巴黎人劇場、倫敦人劇場及金沙劇場舉行的世界級娛樂表演，以及來往港澳的金光飛航高速渡輪服務。公司在路氹金光大道的各物業發展項目，堅定並持續地為建設澳門成為世界旅遊休閒中心貢獻力量。金沙中國是全球度假村發展商拉斯維加斯金沙集團股份有限公司（紐約證券交易所：LVS）的附屬公司。

如欲索取更多相關資訊，請瀏覽網頁https://hk.sandschina.com/index.html。

傳媒查詢：
金沙中國有限公司 – 企業傳訊部
胡美寶
電話：+853 8118 2268
電郵：[email protected] 

鄭文軒
電話：+853 8118 2054
電郵：[email protected]

SHENZHEN, China, June 30, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that its annual general meeting (the "AGM") was held in Hong Kong on June 30, 2026 and all the proposed resolutions set out in the notice of the AGM dated May 20, 2026 were duly passed at the AGM.

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading online music and audio entertainment platform in China, operating the country's highly popular and innovative music apps: QQ Music, Kugou Music, Kuwo Music and WeSing. TME's mission is to create endless possibilities with music and technology. TME's platform comprises online music, online audio, online karaoke, music-centric live streaming and online concert services, enabling music fans to discover, listen, sing, watch, perform and socialize around music. For more information, please visit ir.tencentmusic.com.

Investor Relations Contact
Tencent Music Entertainment Group
[email protected]
+86 (755) 8601-3388 ext. 885034

Seven creators from five continents shared stories of movement while more than 3,000 people joined a community run in Hong Kong

SHENZHEN, China, June 30, 2026 /PRNewswire/ -- TCL, a leading global technology company and a Worldwide Olympic and Paralympic Partner, has concluded its global campaign for Olympic Day 2026, supporting the International Olympic Committee (IOC)'s "Let's Move" initiative celebrating the joy of movement and sport.

The campaign began with seven creators sharing their interpretations of the Olympic spirit through film, family activities, fashion, culture and movement. Their stories were brought together in a montage filmed around the world to spark cross-platform conversations under the brand slogan "Inspire Greatness" and the social media hashtag #JointheGreatness. The celebration then moved into the community with the "Run with Hong Kong Athletes" event on June 28.

"We've seen that the magic of the Olympic Games isn't just in the stadiums; it's in living rooms, streets and communities across the globe. We at TCL are proud to provide new ways for people around the world to connect with this spirit and inspire their own greatness," said Wei Xue, Vice President and ESG Director of TCL Technology and Chairman of the TCL Charity Foundation.

Seven Creators Share One Global Story

The seven creators from five continents, reaching a combined social following of more than 21 million people, explored how the concept of Inspire Greatness and the Olympic spirit take on different cultural meanings worldwide, and how TCL's technology can bring them to life in ways that resonate across cultures.

In the United States, cinematic storytelling paid tribute to the history of film, moving from black-and-white to vivid color. In France, families turned their living rooms into spaces for friendly competition, using games and challenges inspired by the sporting action on screen. In New Zealand, movement drew on Māori heritage and a close connection to the land, while in South Africa, creators brought together sport, fashion and the ambitions of a new generation. In Japan, parkour, gaming-inspired visuals and augmented reality connected movement through the streets of Tokyo, reflecting the energy and determination seen on the sporting stage.

The montage film created one continuous global celebration through seamless transitions between people, places and screens, inviting viewers to share their own experiences under the hashtag #JointheGreatness – whether they tried out a new sport, overcame an everyday challenge, or simply chose to move. By celebrating participation rather than sporting achievement alone, the campaign reflected a central idea behind Olympic Day: everyone can be part of the movement.

Over 3,000 People Join Hong Kong Community Run

The campaign continued in Hong Kong on June 28, when more than 3,000 people took part in the "Run with Hong Kong Athletes" event.

Organized in collaboration with the IOC and the Sports Federation and Olympic Committee of Hong Kong, China, and sponsored by TCL, the event brought the "Let's Move" invitation directly into the local community. Runners of different ages and backgrounds gathered to enjoy sport and experience the Olympic spirit outside the competition arena, celebrating Olympic Day alongside local athletes. TCL hosted a booth on site, helping to provide entertainment for attendees, while more than 30 TCL employees embodied the spirit of "Inspire Greatness" by joining the run.

Following the stories of movement shared across five continents, the Hong Kong runners united to write their own collective chapter, bridging the campaign's message with the physical world.

Bringing the Arena Closer

Display technology played an important role throughout the campaign, helping creators connect sporting moments on screen with real-world movement, and bringing the inspiration of the Olympic Games into everyday life.

TCL SQD-Mini LED TVs combine an expansive picture with advanced color reproduction and fine visual detail. By reproducing the expressions, movement and emotion that define decisive sporting moments, the TVs become an extension of the arena, bringing audiences closer to the action.

The campaign also showcased TCL RayNeo AR glasses, pointing to more personal and immersive ways to enjoy sports entertainment. By placing digital content within the wearer's natural field of view, the glasses offer a large-format viewing experience that can be enjoyed almost anywhere.

A Year-Round Olympic Journey

The Olympic Day campaign continues a year of activities through which TCL has connected technology, sport and local communities.

Ahead of the Olympic and Paralympic Winter Games Milano Cortina 2026, TCL created its "Wishes for Greatness" winter wonderland in Milan's Piazza del Duomo. Additionally, the company opened TCL Edelweiss Land in Milan, where visitors experienced its latest display technology, augmented reality products and smart home appliances. Team TCL built on the same "Inspire Greatness" vision, highlighting that greatness takes many forms by supporting athletes pursuing success at the highest level, while encouraging people everywhere to follow their own ambitions.

From Milan's festive celebrations to the streets of Hong Kong, TCL's role as a Worldwide Olympic and Paralympic Partner extends beyond the events themselves. It represents a long-term commitment to using technology to bring people closer to sport, to one another and to the moments that inspire greatness in everyday life.

About TCL

Founded in 1981, TCL—short for "The Creative Life"—is dedicated to empowering smarter, healthier lifestyles through next-generation experiences. Operating through two independent entities, TCL Industries and TCL Technology, TCL delivers innovative solutions spanning TVs, smartphones, audio products, smart home devices, display technologies, and clean energy. 

Today, with 47 R&D centers and 41 manufacturing bases globally, TCL operates in over 160 countries and regions, reinforcing its position as a globally competitive smart technology brand. To further inspire greatness, TCL has become an official Worldwide Olympic and Paralympic Partner in the Home Audiovisual Equipment and Home Appliances category. 

https://www.tcl.com/global/en 

BEIJING, June 30, 2026 /PRNewswire/ -- New Oriental Education and Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU/ 9901.SEHK), a provider of private educational services in China, today announced that it will report its financial results for the fourth quarter ended May 31, 2026, before the U.S. market opens on July 29, 2026. New Oriental's management will host an earnings conference call at 8 AM on July 29, 2026, U.S. Eastern Time (8 PM on July 29, 2026, Beijing/Hong Kong Time). Participants can join the conference using the below options:

Dialling-in to the conference call:

Please register in advance of the conference, using the link provided below. Upon registering, you will be provided with participant dial-in numbers, and unique personal PIN.

Conference call registration link:

https://register-conf.media-server.com/register/BIffe9352b170044a4b248e41d134aed08. It will automatically direct you to the registration page of "New Oriental FY2026 Q4 Earnings Conference Call" where you may fill in your details for RSVP.

In the 10 minutes prior to the call start time, you may use the conference access information (including dial in number(s) and personal PIN) provided in the confirmation email received at the point of registering.

Joining the conference call via a live webcast:

Additionally, a live and archived webcast of the conference call will be available at http://investor.neworiental.org.

Listening to the conference call replay:

A replay of the conference call may be accessed via the webcast on-demand by registering at https://edge.media-server.com/mmc/p/pdsxxtdn first. The replay will be available until July 29, 2027.

About New Oriental

New Oriental is a provider of private educational services in China offering a wide range of educational programs, services and products to a varied student population throughout China. New Oriental's program, service and product offerings mainly consist of educational services and test preparation courses, private label products and livestreaming e-commerce, overseas study consulting services, and educational materials and distribution. New Oriental is listed on NYSE (NYSE: EDU) and SEHK (9901.SEHK), respectively. New Oriental's ADSs, each of which represents ten common shares, are listed and traded on the NYSE. The Hong Kong-listed shares are fully fungible with the ADSs listed on NYSE.

For more information about New Oriental, please visit http://www.neworiental.org/english/.

Contacts

WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) — together with its Drug Product Packaging Center (DPPC), have received GMP certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The certification positions WuXi Biologics to provide end‑to‑end commercial manufacturing services — covering both drug substance and drug product — for an anti-PD-L1 monoclonal antibody used in cancer immunotherapy.

Based on the five-day inspection, MFG2, DP1 and DPPC successfully passed ANVISA's assessment with zero findings. The inspection results demonstrate WuXi Biologics' robust quality management system, mature GMP execution, and efficient cross-functional collaboration, while verifying the company's comprehensive capabilities to support client needs for global commercial manufacturing and supply.

Within WuXi Biologics' global GMP manufacturing network, MFG2, DP1 and DPPC collectively provide integrated, end-to-end capabilities spanning large-scale biologics drug substance manufacturing, clinical and commercial drug product fill-finish, and customized packaging, meeting regulatory requirements across major markets worldwide. Together, these capabilities enable seamless manufacturing and reliable commercial supply for innovative biologic therapies.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "Receiving ANVISA GMP certification reflects WuXi Biologics' continued commitment to global quality and compliance standards, and further validates our international standards across facilities, quality systems, and GMP execution. Looking ahead, we will continue to leverage our world-class quality system and end-to-end manufacturing capabilities to enable clients' global commercialization strategies, including entry into Latin America. By accelerating the delivery of high-quality, affordable biologics, we are helping to broaden access to innovative biologics for patients around the world."

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's rigorous quality standards. As of the end of 2025, it has successfully passed 46 regulatory inspections, including 22 conducted by the FDA and EMA, and secured 136 facility license approvals. The company also holds an industry-leading record, achieving a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics has passed more than 1,800 GMP quality audits by global clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network. Its world-class quality and compliance capabilities underpin long-standing trust from clients worldwide.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics — from concept to commercialization — for the benefit of patients worldwide*.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Contacts
Business
[email protected] 

Media
[email protected]

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, and Eli Lilly and Company (NYSE: LLY) today jointly announced that they have entered into a distribution and promotion agreement regarding Lilly's CDK4 & 6 inhibitor Verzenios^® (abemaciclib) in mainland China:

• Innovent will be responsible for the importation, marketing, distribution and promotion of Verzenios^® (abemaciclib) in mainland China;
• Lilly will continue to be responsible for manufacturing, supply, and development for the product.

Verzenios^® (abemaciclib), developed by Lilly, is a CDK4 & 6 inhibitor that has been approved in China for multiple indications, including:

(1) Early Breast Cancer: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.
(2) Locally Advanced or Metastatic Breast Cancer:
a) For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:

• In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.
• In combination with fulvestrant for patients who have experienced disease progression following prior endocrine therapy.

b) In combination with imlunestrant: for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who have previously received endocrine therapy.

The product was included in the National Reimbursement Drug List (NRDL) Class B in 2021, becoming the first CDK4 & 6 inhibitor covered by national reimbursement in China. In 2025, it successfully renewed its NRDL listing, achieving full coverage across both early and advanced breast cancer indications.

Under the agreement, Innovent will hold sole commercialization rights for Verzenios^® (abemaciclib) in mainland China, while Lilly, as the Marketing Authorization Holder (MAH), will continue to be responsible for manufacturing, supply, and ongoing product development. This collaboration combines Innovent's experienced oncology commercialization team and extensive market reach in China with Lilly's expertise in innovative medicine development and lifecycle management, further enhancing access to this important therapy and benefiting more breast cancer patients across the country.

Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "We are delighted to further deepen our strategic partnership with Lilly through this eighth collaboration, bringing the number of our partnered, on-market products in China to seven. This also marks the 19^th product in Innovent's portfolio. Enhancing patient access to high-quality, innovative medicines has always been at the core of Innovent's mission. Leveraging our established commercial infrastructure and strong market presence in China, we remain focused on addressing critical unmet needs in major oncology indications. Breast cancer, one of the most prevalent and life–threatening malignancies among women, is a strategic priority within Innovent's oncology portfolio. Through this commercial collaboration with Lilly on Verzenios^® (abemaciclib) – backed by its robust clinical efficacy, comprehensive labeled indications and national reimbursement coverage – we are expanding our presence in this area, laying a solid foundation for our pipeline development and market expansion deliver lasting benefits to patients in breast cancer."

Huzur Devletsah, Lilly Group Vice President and China General Manager, said: "For 150 years, Lilly has remained committed to putting health above all, advancing human health through scientific innovation and expanding access through collaboration. This agreement for Verzenios^® (abemaciclib) is an important step in strengthening patient access in China, combining Lilly's global R&D expertise with Innovent's commercialization capabilities in China. Looking ahead, Lilly will continue to advance its oncology efforts in China. Since the beginning of this year, we have secured approvals for one new medicine (with two indications) and two new additional indications for on market products in China, including Inluriyo^®, which has become the first and currently only approved precision therapy in China only targeting ESR1-mutated advanced breast cancer, accelerating the introduction of globally innovative therapies and addressing unmet medical needs."

About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 19 products in the market. It has 1 asset in NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Takeda, Pfizer, Roche, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. 

Statement:
1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo), Pirtobrutinib (Jaypirca) and abemaciclib (Verzenios) were developed by Eli Lilly and Company.
Disclaimer: Innovent does not recommend any off-label usage.

About Lilly 
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

Forward-Looking Statements of Innovent Biologics
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

LENOVO GROUP (00992.HK) is not only a long-term agreement customer of Micron Technology, Inc. (MU.US), but has also signed long-term supply agreements for storage products with Samsung and SK Hynix, Shanghai Securities News cited sources as saying.

LENOVO GROUP's China infrastructure business is radically raising its server business growth expectations, according to hearsay. The company previously set a server business target of RMB100 billion for FY2027/2028.

Based on currently executing orders, the confirmable revenue delivery scale from only two major customers next year has already approached RMB200 billion.
~

AASTOCKS Financial News
Website: www.aastocks.com

Samsung Electronics, SK Hynix and Micron Technology, Inc. (MU.US) are facing an antitrust lawsuit in the US. The three companies are accused of manipulating DRAM prices by deliberately reducing the supply of conventional DRAM under the pretext of expanding production of HBM, thereby driving up prices.

The plaintiffs include 14 US consumers and three small and medium-sized PC assembly and distribution companies. They alleged that the three companies have systematically restricted DRAM supply since 2022, giving rise to prices surging by about 700% over the past four years.

The plaintiffs contend that the defendants used inventory management as a justification to cut output, while in reality artificially creating shortages to raise prices.
~

AASTOCKS Financial News
Website: www.aastocks.com